Rapid Release Capsules Melatoni

PreclinicalSmall molecule

Rapid Release Capsules Melatoni is one of 29 small molecule programs targeting Oral Lichen Planus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral Lichen PlanusActive, not recruiting

Oral Lichen PlanusPreclinical

Active, not recruiting

Competition

Competitive Landscape

81 competitors in Oral Lichen Planus

#DrugCompanyPhaseTrials

Azulfidine

Pfizer

Phase 3

1 2

Decadron

AAspen Global Incorporated

Phase 3

3 3

Elidel

BBausch Health Americas, Inc.

Phase 3

2 4

Minocin

TTriax

Phase 3

1 5

PROCRIT

WWim Janssens

Phase 3

1 6

Advil

KKenvue Brands

Phase 3

1 7

Curcumin

Merck & Co.

Phase 3

1 8

Plaquenil

Alnylam Pharmaceuticals

Phase 2

1 9

Olumiant

Eli Lilly

Phase 2

1 10

Olux

HHarrow Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral Lichen Planus1 trial

Melatonin Epigenetic Potential in Preventing Malignant Transformation of Oral Lichen Planus

Active, not recruiting·HHams Hamed Abdelrahman·N/A·NCT06533033·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rapid Release Capsules Melatoni. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rapid Release Capsules Melatoni compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rapid Release Capsules Melatoni. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hams Hamed Abdelrahman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHams Hamed Abdelrahman

Rapid Release Capsules Melatoni

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral Lichen Planus1 trial

References

Drug Info

Quick Facts

Related News